Asundexian (brand name Sunharbo) is a new once-daily pill for adults who have just had a mild-to-moderate ischaemic stroke or a high-risk mini-stroke (TIA) that did not come from a clot in the heart. It is taken on top of aspirin or another antiplatelet drug, and in its main trial it cut the risk of another ischaemic stroke by about a quarter without a clear rise in major bleeding overall.
The US Food and Drug Administration approved it on 9 November 2026. It is the first drug in a new class called factor XIa inhibitors. It is not a replacement for warfarin or apixaban, and it is not approved for people with atrial fibrillation. Here’s who it is meant for, how it works and what the trial actually showed.
What the FDA approved
According to the FDA announcement, Sunharbo 50 mg tablets are approved for use with antiplatelet therapy to reduce the risk of stroke in adults after:
- a recent mild-to-moderate non-cardioembolic ischaemic stroke (a stroke caused by a clot that did not start in the heart), or
- a high-risk transient ischaemic attack (TIA), sometimes called a mini-stroke.
The dose is one 50 mg tablet once a day. Bayer makes it. The FDA gave it Fast Track and Priority Review status, which speed up review for drugs aimed at serious conditions.
China’s regulator approved it in October 2026, a few weeks before the US. Applications in the European Union and Japan were still under review at the time of the US approval. We couldn’t find any decision yet from the UK’s MHRA or India’s drug regulator, so if you live outside the US or China, it is probably not available to you yet.
Who the new stroke pill is for (and who it isn’t)
Most strokes are ischaemic, meaning a clot blocks blood flow to part of the brain. Doctors split these by where the clot came from, because that decides the treatment.
| Situation | Usual prevention after a stroke or TIA | Where asundexian fits |
|---|---|---|
| Clot from narrowed or damaged arteries, or small-vessel disease (non-cardioembolic) | Antiplatelets such as aspirin or clopidogrel, plus blood pressure, cholesterol and lifestyle control | Approved in the US as an add-on to antiplatelets after a recent mild-to-moderate stroke or high-risk TIA |
| Clot from the heart, most often due to atrial fibrillation (AF) | An anticoagulant such as apixaban, rivaroxaban, edoxaban, dabigatran or warfarin | Not approved. It did worse than apixaban in AF (see below) |
| Bleeding stroke (haemorrhagic) | Blood pressure control and treating the cause | Not relevant. Blood thinners are generally avoided |
In the trial, “mild-to-moderate” meant a score of 15 or less on the NIH Stroke Scale, the checklist doctors use in hospital to grade how severe a stroke is. So people who had a large, disabling stroke were not studied.
How asundexian works
Your blood clots through a chain of proteins called clotting factors. Older anticoagulants act at the main junctions of that chain: warfarin lowers several factors at once, and the newer pills (often called DOACs or NOACs) block either factor Xa or thrombin. That stops harmful clots well, but it also blunts the clotting you need to seal a cut or a leaking blood vessel. Bleeding is their main downside.
Factor XI sits further up the chain and mostly helps a clot grow bigger once it has started. A 2023 review in the Journal of Clinical Medicine explains the idea: blocking factor XIa may curb the runaway clotting that blocks arteries while leaving enough of the normal clotting pathway to stop bleeding. Part of the evidence comes from people born with factor XI deficiency, who tend to have fewer clots without the severe bleeding seen in some other clotting disorders.
That is the theory. The trials are what tell you whether it holds up.
What the OCEANIC-STROKE trial found
The approval rests on one large phase 3 study, published in the New England Journal of Medicine in April 2026 and summarised by the American College of Cardiology. It enrolled 12,327 adults within 72 hours of their stroke or TIA symptoms starting. Everyone got single or dual antiplatelet therapy. Half also got asundexian 50 mg daily and half got a dummy pill.
| Result | Asundexian + antiplatelet | Placebo + antiplatelet |
|---|---|---|
| Ischaemic stroke during follow-up | 6.2% | 8.4% |
| Major bleeding | 1.9% | 1.7% |
| Median follow-up | 567 days (about 19 months) | 567 days (about 19 months) |
In plain numbers, that is a 26% relative drop in repeat ischaemic strokes, or about 2 fewer strokes for every 100 people treated over that period. The difference in major bleeding was small and not statistically significant.
A few details matter if you’re weighing it up:
- The benefit over the first 90 days on its own was not statistically clear (3.0% versus 3.5%). Much of the gain built up over the longer follow-up.
- The FDA notes that major bleeding was higher with asundexian in people older than 75 and during the first 90 days of treatment.
- Bleeding from the gut was more common with asundexian.
- Diarrhoea was the most common side effect, at roughly 3% of people.
Asundexian vs aspirin, clopidogrel, warfarin and apixaban
People often lump all of these together as “blood thinners”, but they do different jobs. MedlinePlus separates them into two groups: antiplatelets (aspirin, clopidogrel) stop platelets clumping, while anticoagulants (warfarin, heparin and the newer pills) slow the clotting chain itself.
- Versus aspirin or clopidogrel: asundexian does not replace them. It is added to them.
- Versus warfarin or apixaban: these remain the drugs for stroke prevention in atrial fibrillation. Asundexian was tested head to head against apixaban in AF and lost.
- Monitoring: unlike warfarin, there is no routine INR blood test, and it is a fixed dose.
That AF trial is worth knowing about. In OCEANIC-AF, which the ACC reported in 2024, 14,810 people with atrial fibrillation took either asundexian or apixaban. Stroke or a clot elsewhere in the body happened in 1.3% on asundexian versus 0.4% on apixaban, and the trial was stopped early. Asundexian did cause less major bleeding (0.2% versus 0.7%), but it simply didn’t protect well enough against clots coming from the heart. So if you have AF, do not expect to be switched to it.
Side effects, interactions and safety checks
From the FDA’s approval summary, your doctor will want to know about:
- Other medicines. It is not recommended with drugs that strongly speed up certain liver enzymes and a drug pump (combined P-gp and strong CYP3A4 inducers), such as the epilepsy drug carbamazepine. These can make asundexian less effective. Give your doctor a full list, including herbal products.
- Liver disease. It is not recommended in moderate or severe liver impairment.
- Surgery and dental work. It should be stopped at least 24 hours before planned surgery or invasive procedures.
- Clot-busting treatment. It should not be given for at least 24 hours after thrombolysis for an acute stroke.
Because you’ll be on an antiplatelet as well, watch for the bleeding signs MedlinePlus lists: red or brown urine, red or black stools, nosebleeds or gum bleeding that won’t stop, brown or bright red vomit, coughing up something red, unusual bruising, and periods much heavier than normal.
Cost may be the biggest practical barrier. Bayer’s US list price is $748.50 for a 30-day supply, though what you pay depends on your insurance, and Bayer runs a patient assistance programme.
What doesn’t change after a stroke or TIA
A new pill adds to the basics. It doesn’t replace them. The NHS describes a TIA as a warning sign that a full stroke may follow soon, and advises being assessed by a specialist within 24 hours, even if the symptoms have gone.
The things that cut your risk most are still:
- keeping blood pressure under control (it tends to creep up in cold weather; here’s why blood pressure rises in winter)
- taking your prescribed antiplatelet and cholesterol medicine every day
- stopping smoking, cutting down on alcohol and staying active
- managing diabetes if you have it
When to see a doctor or get emergency help
Call your local emergency number (911 in the US, 999 in the UK, 112 in the EU and India) straight away if you or someone near you has any of these, even if they pass quickly:
- face drooping on one side, or a lopsided smile
- weakness or numbness in an arm or leg
- slurred or confused speech, or trouble understanding
- sudden loss of vision, balance problems or a sudden severe headache
- on a blood thinner: vomiting blood, black stools, a head injury, or bleeding that won’t stop
Our guide to BE FAST stroke signs and the first hour walks through what to do while you wait. If someone collapses and isn’t breathing normally, start CPR. And if you’re unsure whether chest discomfort is your heart, read how to tell gas from a heart attack, but don’t wait at home to find out.
Book a regular appointment if you had a stroke or TIA in the past and want to ask whether asundexian suits you. Bring your medicine list and ask how the bleeding risk applies to your age.
Frequently asked questions
Is asundexian a blood thinner?
Yes. It is an anticoagulant that blocks factor XIa, a different target from warfarin or apixaban. In the US it is taken together with an antiplatelet such as aspirin or clopidogrel.
Can I switch from apixaban to asundexian?
Not if you take apixaban for atrial fibrillation. Asundexian is not approved for AF, and in a large trial it prevented fewer strokes than apixaban in people with AF.
Does asundexian cause less bleeding?
In the stroke trial, overall major bleeding was similar to placebo (1.9% versus 1.7%). But bleeding was higher in people over 75 and in the first 90 days, and gut bleeding was more common.
Is asundexian available in the UK, EU or India?
Not yet, as far as we can confirm. It is approved in the US and China, and was under review in the EU and Japan when the US approved it.
How long do you take it after a stroke?
The trial followed people for a median of about 19 months. Your neurologist or stroke team will decide how long it makes sense for you, as longer-term data are still being collected.
This article is for general information and is not a substitute for advice from a doctor. If you have symptoms or a health condition, please consult a qualified healthcare professional.

